Stockscreener 앱 받기
68.72
0.10%
-0.07
시간 외 거래:
68.95
0.23
+0.33%
전일 마감가:
$68.79
열려 있는:
$68.875
하루 거래량:
3.20M
Relative Volume:
0.72
시가총액:
$213.12B
수익:
$54.98B
순이익/손실:
$7.77B
주가수익비율:
27.60
EPS:
2.49
순현금흐름:
$9.14B
1주 성능:
-4.21%
1개월 성능:
-1.76%
6개월 성능:
+1.12%
1년 성능:
-12.69%
1일 변동 폭
$68.61
$69.37
1주일 범위
$68.61
$71.81
52주 변동 폭
$61.24
$87.67
아스트라제네카 ADR Stock (AZN) Company Profile
명칭
Astrazeneca PLC
전화
44 20 3749 5000
주소
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
AZN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
68.72 | 222.43B | 54.98B | 7.77B | 9.14B | 2.49 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-12 | 개시 | Morgan Stanley | Overweight |
| 2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
| 2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
AstraZeneca to invest $50B in US by 2030 - breakingthenews.net
AstraZeneca picks Virginia for multibillion-dollar manufacturing site - Richmond Times-Dispatch
AstraZeneca to spend $50-billion to expand manufacturing, research capabilities in U.S. - The Globe and Mail
AstraZeneca PLC (AZN)’s Datroway Wins FDA Nod for Lung Cancer Breakthrough - Yahoo Finance
AstraZeneca Vows to Spend $50 Billion on US Manufacturing, Development - Bloomberg.com
What analysts say about AstraZeneca PLC Depositary Receipt stockPowerful profit generation - Autocar Professional
AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer - Benzinga
AstraZeneca Plans Massive $50B US Investment: New Virginia Mega-Factory to Create Thousands of Jobs - Stock Titan
AstraZeneca unveils $50 billion US investment as pharma tariff threat looms - MarketScreener
AstraZeneca’s Observational SLE Study in Kazakhstan: Key Insights for Investors - TipRanks
AstraZeneca’s Promising Pediatric SLE Study: Anifrolumab’s Potential Impact - TipRanks
AstraZeneca’s New Phase II Study: A Potential Breakthrough in Liver Cancer Treatment - TipRanks
AstraZeneca’s COPD Study: Potential Game-Changer for Cardiopulmonary Outcomes - TipRanks
AstraZeneca’s AIRSUPRA Study: A Potential Game-Changer in Asthma Treatment - TipRanks
AstraZeneca reports positive results from Tagrisso combo trial - Seeking Alpha
AstraZeneca’s lung cancer drug shows improved survival with chemotherapy combo - Investing.com UK
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. (TEM) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Is it worth me buying more AstraZeneca shares at just over £13? - yahoo.co
What drives AstraZeneca PLC Depositary Receipt stock priceBreakthrough profit margins - PrintWeekIndia
Is AstraZeneca PLC Depositary Receipt a good long term investmentUnrivaled growth potential - jammulinksnews.com
AstraZeneca PLC Depositary Receipt Stock Analysis and ForecastHigh-performance investment picks - Autocar Professional
Is AstraZeneca (AZN) a Reliable Dividend Stock for Long-Term Investors? - Yahoo Finance
AstraZeneca’s Latest Study on Dato-DXd for NSCLC: Key Insights for Investors - TipRanks
AstraZeneca’s CASPIAN Study: A Promising Update in Lung Cancer Treatment - TipRanks
AstraZeneca’s Benralizumab Study: Real-World Insights for Severe Asthma - TipRanks
AstraZeneca’s PRIMULA Lac Study: A Key Step in Anifrolumab’s Market Journey - TipRanks
AstraZeneca’s AZD5004 Study: A New Hope for Type 2 Diabetes Treatment? - TipRanks
AstraZeneca’s Anifrolumab Study: A Potential Game-Changer for SLE Treatment - TipRanks
AstraZeneca’s Pediatric Hyperkalaemia Study: A Potential Game-Changer - TipRanks
AstraZeneca’s AQUALIS Study: Enhancing CLL Patient Quality of Life with Acalabrutinib - TipRanks
AstraZeneca’s DESTINY-Endometrial01 Study: A New Hope for Endometrial Cancer Treatment - TipRanks
AstraZeneca’s REBECCA Study: Real-World Insights into Early Breast Cancer Management - TipRanks
AstraZeneca’s Moxetumomab Pasudotox Safety Study Terminated: Market Implications - TipRanks
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies - MSN
AstraZeneca’s Promising Study on Endometrial Cancer Treatment - TipRanks
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know - sharewise.com
Contact Levi & Korsinsky by February 21, 2025 Deadline to Join Class Action Against AstraZeneca PLC(AZN) - MarketScreener
AstraZeneca’s New Study Sheds Light on COPD Burden in Egypt - TipRanks
AstraZeneca’s INTERSTELLAR Study: Real-World Insights into Anifrolumab for Lupus - TipRanks
AstraZeneca and Bayer’s Collaborative Study on Metastatic Prostate Cancer: A Potential Game-Changer? - TipRanks
AstraZeneca’s DAISY Study: A New Hope for Systemic Sclerosis Treatment - TipRanks
AstraZeneca’s OPTIMISE-CKD Study: A Closer Look at Chronic Kidney Disease Management in Spain - TipRanks
AstraZeneca’s Real-Life Study on Benralizumab: Market Implications and Progress - The Globe and Mail
AstraZeneca’s AI-Driven Breast Cancer Risk Study: A New Frontier in Personalized Medicine - TipRanks
AstraZeneca’s Dapagliflozin Study: A New Hope for Chronic Kidney Disease in China - TipRanks
AstraZeneca’s New Phase III Study: A Potential Game-Changer in Biliary Tract Cancer Treatment - TipRanks
AstraZeneca’s iCaReMe Global Registry: A Real-World Data Initiative - TipRanks
AstraZeneca Completes Phase II Asthma Study: Market Implications and Insights - TipRanks
AstraZeneca’s Phase III Study on Benralizumab: A Potential Game-Changer for Pediatric Asthma - TipRanks
AstraZeneca, Daiichi Sankyo get U.S. breakthrough therapy status for Enhertu - Seeking Alpha
AstraZeneca Loses Bid To Revive Patent For Diabetes Drug - Law360
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):